Long-term clearance of linear porokeratosiswith tacrolimus, 0.1%, ointment

JAMA Dermatology

Volumn 150, Issue 2, 2014, Pages 194-196

  Parks, Ashley C ^a   Conner, Kelly J ^a   Armstrong, Cheryl A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; ETRETIN; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DERMATITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; PAPULE; PARAKERATOSIS; PARESTHESIA; POROKERATOSIS; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; POROKERATOSIS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894574108     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.8526     Document Type: Article

References (6)

1. Rahbari H, Cordero AA, Mehregan AH. Linear porokeratosis: a distinctive clinical variant of porokeratosis of Mibelli. Arch Dermatol. 1974;109(4):526-528.
2. Sasson M, Krain AD. Porokeratosis and cutaneous malignancy: a review. Dermatol Surg. 1996;22(4):339-342. (Pubitemid 26144657)
3. Goldman GD,Milstone LM. Generalized linear porokeratosis treated with etretinate. Arch Dermatol. 1995;131(4):496-497.
4. Lee Y, Choi EH. Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae. J Dermatol. 2011;38(11):1072-1075.
5. Simpson D, Noble S. Tacrolimus ointments. Drugs. 2005;65(6):827-858.
6. Büchau AS, Schauber J, Hultsch T, Stuetz A, Gallo RL. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol. 2008;128(11):2646-2654.